Lung Cancer News and Research

Latest Lung Cancer News and Research

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.

10 Dec 2010

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

10 Dec 2010

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

People exposed to North Dakota road materials face increase risk of developing mesothelioma

New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

10 Dec 2010

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

10 Dec 2010

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.

10 Dec 2010

Tobacco-cessation expert receives 2011 ASPO Joseph W. Cullen Memorial Award tobacco research

Behavioral scientist and tobacco-cessation expert, Alexander V. Prokhorov, M.D., Ph.D., at The University of Texas MD Anderson Cancer Center is the recipient of the 2011 American Society of Preventive Oncology (ASPO) Joseph W. Cullen Memorial Award for Excellence in Tobacco Research.

10 Dec 2010

Collegium Ramazzini repeats calls for total global ban on all asbestos

Scientists at the Collegium Ramazzini in Modena, Italy have repeated calls for a total ban on all asbestos across the globe. Writing in the International Journal of Environment and Health, the Collegium points out that just 52 nations have banned asbestos but a large number still use, import and export asbestos and asbestos-containing products.

9 Dec 2010

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer.

9 Dec 2010

Smoking cessation products available on PBS

Australia’s federal government has announced that it will subsidize the cost of nicotine patches to help smokers quit. The announcement was made by Health Minister Nicola Roxon on Thursday who said that concession card holders would be able to access Nicorette, Nicabate P and Nicotinell under the Pharmaceutical Benefits Scheme (PBS) from February 1, 2011. She said, “Cancer scars the lives of too many Australians and we know that reducing the smoking rate is one of the most effective ways to reduce the rate of death from this terrible disease.” Anti-smoking drug Varenicline (Champix) would also be available for willing quitters.

8 Dec 2010

ChipDX validates genetic signature for early-stage colon cancer

ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.

8 Dec 2010

Humble aspirin reduces cancer death rates

A new study has shown aspirin cuts down the death rates from a range of cancers. The study reviewed data from eight previous trials involving more than 25,000 patients found that those who took just 75mg of aspirin a day (one-eighth of a normal dose) could reduce their death rates from cancer by 21% with benefits continuing long after patients stopped taking the pill.

7 Dec 2010

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the presentation of the CRS-207 Phase 1 study at the AACR Special Conference on Tumor Immunology in Miami, Florida by the Principal Investigator, Dr. Dung Le of the Johns Hopkins Kimmel Cancer Center. Dr. Le reported that CRS-207 intravenous administration was well tolerated in subjects with advanced, treatment-refractory cancers. Dr. Le also reported evidence of immune activation and that 6 out of 17 end-stage cancer patients lived 15 months or longer.

7 Dec 2010

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

A study published in the December issue of The Journal of Nuclear Medicine identified positron emission tomography/computed tomography (PET/CT) scans as a potentially useful tool for predicting local recurrence in lung cancer patients treated with radiofrequency ablation (RFA). RFA, which uses localized thermal energy to kill cancer cells, is increasingly used as an alternative treatment for patients unable to undergo surgery or other therapies to treat lung cancer.

7 Dec 2010

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.

7 Dec 2010

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.

7 Dec 2010

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

ZIOPHARM Oncology, Inc. announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology in Orlando Florida.

6 Dec 2010

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.

6 Dec 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

People exposed to North Dakota road materials face increase risk of developing mesothelioma

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Tobacco-cessation expert receives 2011 ASPO Joseph W. Cullen Memorial Award tobacco research

Collegium Ramazzini repeats calls for total global ban on all asbestos

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Smoking cessation products available on PBS

ChipDX validates genetic signature for early-stage colon cancer

Humble aspirin reduces cancer death rates

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

The ultimate guide to lung research tools and protocols eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in